Syndax Pharmaceuticals, Inc. (SNDX) Financial Statements (2024 and earlier)

Company Profile

Business Address 35 GATEHOUSE DRIVE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments475,802439,936293,06559,77580,911129,974
Cash and cash equivalents74,356221,965115,24324,60933,76935,168
Short-term investments401,446217,971177,82235,16647,14294,806
Restricted cash and investments 115   101106
Receivables583429175116253377
Prepaid expense8861,022802727621670
Deposits current assets8,5956,8944,6831,2976631,286
Other undisclosed current assets3,8051151394167971,029
Total current assets:489,786448,396298,86462,33183,346133,442
Noncurrent Assets
Operating lease, right-of-use asset1,039983290716
Property, plant and equipment20278192281373267
Long-term investments and receivables5,469    3,246
Long-term investments5,469    3,246
Restricted cash and investments115     
Other noncurrent assets807 1,267197219231
Total noncurrent assets:7,4501,2611,7491,1945923,744
TOTAL ASSETS:497,236449,657300,61363,52583,938137,186
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,25112,3757,6229,6474,8625,048
Employee-related liabilities4,3423,2132,8002,8042,393
Accounts payable4,3505,6693,5086,1781,4392,232
Accrued liabilities7,9012,364901669619423
Deferred revenue   1,5171,517
Debt   2,285478  
Derivative instruments and hedges, liabilities  187    
Deferred revenue and credits1,573
Contract with customer, liability1,517
Other undisclosed current liabilities16,8148,1217,4486,7269,7269,177
Total current liabilities:29,06520,68318,87218,36816,10515,798
Noncurrent Liabilities
Long-term debt and lease obligation  20,60617,935419  
Long-term debt, excluding current maturities  19,89517,834   
Liabilities, other than long-term debt709 11,61813,13814,78617,069
Deferred revenue and credits16,759
Deferred revenue   11,61713,133
Contract with customer, liability14,650
Other liabilities   15136310
Operating lease, liability709711101419
Other undisclosed noncurrent liabilities13(711)    
Total noncurrent liabilities:72220,60629,55313,55714,78617,069
Total liabilities:29,78741,28948,42531,92530,89132,867
Equity
Equity, attributable to parent467,449408,368252,18831,60053,047104,319
Common stock765322
Additional paid in capital1,161,288952,019820,815527,067492,493470,571
Accumulated other comprehensive income (loss)(806)45(4) (25)(143)
Accumulated deficit(693,040)(543,702)(568,628)(495,470)(439,423)(366,111)
Total equity:467,449408,368252,18831,60053,047104,319
TOTAL LIABILITIES AND EQUITY:497,236449,657300,61363,52583,938137,186

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues  139,7091,5171,5171,5172,108
Revenue, net2,108
Gross profit:  139,7091,5171,5171,5172,108
Operating expenses(151,757)(113,489)(72,940)(59,056)(77,393)(64,062)
Operating income (loss):(151,757)26,220(71,423)(57,539)(75,876)(61,954)
Nonoperating income (expense)2,419(1,294)(1,735)1,4921,9151,152
Investment income, nonoperating5,872403841   
Other nonoperating income (expense)(316)202(219)(79)(27)(269)
Interest and debt expense(3,137)(1,899)(2,357)   
Income (loss) from continuing operations:(152,475)23,027(75,515)(56,047)(73,961)(60,802)
Income (loss) before gain (loss) on sale of properties:23,027(75,515)(56,047)(73,961)(60,802)
Other undisclosed net income3,1371,8992,357   
Net income (loss):(149,338)24,926(73,158)(56,047)(73,961)(60,802)
Other undisclosed net income attributable to parent      
Net income (loss) attributable to parent:(149,338)24,926(73,158)(56,047)(73,961)(60,802)
Other undisclosed net loss available to common stockholders, basic   (3,906)   
Net income (loss) available to common stockholders, diluted:(149,338)24,926(77,064)(56,047)(73,961)(60,802)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(149,338)24,926(73,158)(56,047)(73,961)(60,802)
Comprehensive income (loss):(149,338)24,926(73,158)(56,047)(73,961)(60,802)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(851)49(4)25118(199)
Comprehensive income (loss), net of tax, attributable to parent:(150,189)24,975(73,162)(56,022)(73,843)(61,001)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: